微rna 142-5p、182-3p和99a-3p在局部晚期直肠癌患者中的预后作用

IF 1.7 4区 医学 Q4 ONCOLOGY
Linda Kokaine, Zanda Daneberga, Mihails Šatcs, Daniella Zvina, Inga Naļivaiko, Jurijs Nazarovs, Andris Gardovskis, Miki Nakazawa-Miklaševiča, Edvīns Miklaševičs
{"title":"微rna 142-5p、182-3p和99a-3p在局部晚期直肠癌患者中的预后作用","authors":"Linda Kokaine, Zanda Daneberga, Mihails Šatcs, Daniella Zvina, Inga Naļivaiko, Jurijs Nazarovs, Andris Gardovskis, Miki Nakazawa-Miklaševiča, Edvīns Miklaševičs","doi":"10.21873/anticanres.17748","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>MicroRNAs (miRNAs) are likely to play a significant role in predicting rectal cancer response to chemoradiation therapy and overall cancer prognosis, offering insights that complement other biological tumor markers. This study aimed to conduct miRNA profiling in rectal cancer tissues in patients with good (GR) and bad response (BR) to neoadjuvant chemoradiation therapy (nCRT), followed by the selection of clinically relevant miRNAs. The relationship between selected miRNAs and subsequent disease outcomes and survival prognosis was assessed.</p><p><strong>Patients and methods: </strong>Forty patients with locally advanced rectal cancer who received nCRT followed by surgical treatment at the Pauls Stradiņš Clinical University Hospital during the period from 2016 to 2021 were included in the study. Two study groups were created, GR and BR, according to the Dworak tumor regression grading (TRG) system. The identification of 752 miRNAs was conducted in rectal cancer tissues according to the protocol of miRCURY LNA miRNA miRNome PCR Panels. Six up-regulated miRNAs were deemed as clinically significant and subsequently validated in both the BR and GR groups.</p><p><strong>Results: </strong>MiR-142-5p, miR-182-3p, and miR-99a-3p exhibited statistical significance in the validation procedure. The results showed that BR to nCRT, lower expression of miRNA-142-5p and miR-99a-3p, and higher expression of miR-182-3p were associated with a trend toward worse local recurrence-free survival, distant metastases-free survival, and overall survival.</p><p><strong>Conclusion: </strong>MiRNAs may potentially serve as clinical biomarkers in the prediction of disease-free survival and overall survival in patients with rectal cancer.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3895-3912"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Prognostic Role of microRNAs 142-5p, 182-3p, and 99a-3p in Locally Advanced Rectal Cancer Patients.\",\"authors\":\"Linda Kokaine, Zanda Daneberga, Mihails Šatcs, Daniella Zvina, Inga Naļivaiko, Jurijs Nazarovs, Andris Gardovskis, Miki Nakazawa-Miklaševiča, Edvīns Miklaševičs\",\"doi\":\"10.21873/anticanres.17748\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>MicroRNAs (miRNAs) are likely to play a significant role in predicting rectal cancer response to chemoradiation therapy and overall cancer prognosis, offering insights that complement other biological tumor markers. This study aimed to conduct miRNA profiling in rectal cancer tissues in patients with good (GR) and bad response (BR) to neoadjuvant chemoradiation therapy (nCRT), followed by the selection of clinically relevant miRNAs. The relationship between selected miRNAs and subsequent disease outcomes and survival prognosis was assessed.</p><p><strong>Patients and methods: </strong>Forty patients with locally advanced rectal cancer who received nCRT followed by surgical treatment at the Pauls Stradiņš Clinical University Hospital during the period from 2016 to 2021 were included in the study. Two study groups were created, GR and BR, according to the Dworak tumor regression grading (TRG) system. The identification of 752 miRNAs was conducted in rectal cancer tissues according to the protocol of miRCURY LNA miRNA miRNome PCR Panels. Six up-regulated miRNAs were deemed as clinically significant and subsequently validated in both the BR and GR groups.</p><p><strong>Results: </strong>MiR-142-5p, miR-182-3p, and miR-99a-3p exhibited statistical significance in the validation procedure. The results showed that BR to nCRT, lower expression of miRNA-142-5p and miR-99a-3p, and higher expression of miR-182-3p were associated with a trend toward worse local recurrence-free survival, distant metastases-free survival, and overall survival.</p><p><strong>Conclusion: </strong>MiRNAs may potentially serve as clinical biomarkers in the prediction of disease-free survival and overall survival in patients with rectal cancer.</p>\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 9\",\"pages\":\"3895-3912\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17748\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17748","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:MicroRNAs (miRNAs)可能在预测直肠癌对放化疗的反应和整体癌症预后方面发挥重要作用,为其他生物肿瘤标志物提供补充。本研究旨在对新辅助放化疗(nCRT)反应良好(GR)和不良反应(BR)患者的直肠癌组织进行miRNA谱分析,并选择临床相关的miRNA。评估选定的mirna与随后的疾病结局和生存预后之间的关系。患者和方法:2016 - 2021年在paul Stradiņš临床大学医院接受nCRT术后手术治疗的局部晚期直肠癌患者40例纳入研究。根据Dworak肿瘤消退分级(TRG)系统分为GR和BR两个研究组。根据miRCURY LNA miRNA miRNome PCR panel的方案,在直肠癌组织中鉴定了752个miRNA。6个上调的mirna被认为具有临床意义,并随后在BR组和GR组中得到验证。结果:MiR-142-5p、miR-182-3p、miR-99a-3p在验证过程中具有统计学意义。结果显示,与nCRT相比,miRNA-142-5p和miR-99a-3p的低表达以及miR-182-3p的高表达与局部无复发生存期、远处无转移生存期和总生存期的恶化趋势相关。结论:mirna有可能作为预测直肠癌患者无病生存期和总生存期的临床生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Prognostic Role of microRNAs 142-5p, 182-3p, and 99a-3p in Locally Advanced Rectal Cancer Patients.

Background/aim: MicroRNAs (miRNAs) are likely to play a significant role in predicting rectal cancer response to chemoradiation therapy and overall cancer prognosis, offering insights that complement other biological tumor markers. This study aimed to conduct miRNA profiling in rectal cancer tissues in patients with good (GR) and bad response (BR) to neoadjuvant chemoradiation therapy (nCRT), followed by the selection of clinically relevant miRNAs. The relationship between selected miRNAs and subsequent disease outcomes and survival prognosis was assessed.

Patients and methods: Forty patients with locally advanced rectal cancer who received nCRT followed by surgical treatment at the Pauls Stradiņš Clinical University Hospital during the period from 2016 to 2021 were included in the study. Two study groups were created, GR and BR, according to the Dworak tumor regression grading (TRG) system. The identification of 752 miRNAs was conducted in rectal cancer tissues according to the protocol of miRCURY LNA miRNA miRNome PCR Panels. Six up-regulated miRNAs were deemed as clinically significant and subsequently validated in both the BR and GR groups.

Results: MiR-142-5p, miR-182-3p, and miR-99a-3p exhibited statistical significance in the validation procedure. The results showed that BR to nCRT, lower expression of miRNA-142-5p and miR-99a-3p, and higher expression of miR-182-3p were associated with a trend toward worse local recurrence-free survival, distant metastases-free survival, and overall survival.

Conclusion: MiRNAs may potentially serve as clinical biomarkers in the prediction of disease-free survival and overall survival in patients with rectal cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Anticancer research
Anticancer research 医学-肿瘤学
CiteScore
3.70
自引率
10.00%
发文量
566
审稿时长
2 months
期刊介绍: ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信